Preclinical study finds antitumor effects of bispecific antibody
Chugai Pharmaceutical announced today that the preclinical study findings on its original bispecific antibody ERY974, a molecule that binds Glypican-3 and CD3 simultaneously, and that is currently under development as a Phase ...
Oct 5, 2017